(±)-Blebbistatin (Synonyms: (S)Blebbistatin) |
| Catalog No.GC12341 |
(±)-블레비스타틴은 선택적 비근육 미오신 II(NMII) 억제제로, 각막 내피 세포(CEC)의 방향성 이동을 촉진하고 상처 치유를 가속화하며, 세포 접합부 완전성과 장벽 기능을 더 잘 보존합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 674289-55-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(±)-Blebbistatin is a racemic mixture containing two configurations, (+)-Blebbistatinb and (-)-Blebbistatin (Cat. No. GC13430). (±)-Blebbistatin can effectively inhibit the activity of non-muscle myosin II ATPase and the expression of various striated muscle myosins and non-muscle myosins in vertebrates[1, 2]. (±)-Blebbistatin is a commonly used excitation-contraction uncoupling agent in cardiovascular physiology[3]. (±)-Blebbistatin is a potential photodynamic drug that can kill cancer cells. Exposure to UV light with a wavelength below 488nm can also lead to rapid inhibition of (±)-Blebbistatin[4].
In vitro, (±)-Blebbistatin (0.1, 0.5, 2, 10μM) treated rat ventricular myocytes for 10min prevented cell shortening in a dose-dependent manner with an IC50 of 0.43μM, but did not affect intracellular calcium transients ([Ca2+]i)[5].
In vivo, (±)-Blebbistatin (125nM/kg) treated rats with detrusor overactivity (DO) by intravesical instillation significantly reduced the detrusor overactivity index, non-micturition contraction amplitude, and non-micturition contraction frequency, and improved urine storage without impairing urination function[6]. (±)-Blebbistatin (125nM/kg) treated DO rats by intra-arterial injection attenuated 13-cis-RA-induced changes in cystometric parameters and central and peripheral neurotrophic factor levels, and also had antidepressant-like effects[7].
References:
[1]Lucas‐Lopez C, Patterson S, Blum T, et al. Absolute Stereochemical Assignment and Fluorescence Tuning of the Small Molecule Tool,(–)‐Blebbistatin[J]. 2005.
[2]Limouze J, Straight A F, Mitchison T, et al. Specificity of blebbistatin, an inhibitor of myosin II[J]. Journal of Muscle Research & Cell Motility, 2004, 25: 337-341.
[3]George S A , Lin Z , Efimov I R .Simultaneous triple-parametric optical mapping of transmembrane potential, intracellular calcium and NADH for cardiac physiology assessment[J].Communications Biology, 2024.
[4]Sakamoto T, Limouze J, Combs C A, et al. Blebbistatin, a myosin II inhibitor, is photoinactivated by blue light[J]. Biochemistry, 2005, 44(2): 584-588.
[5]Fedorov V V, Lozinsky I T, Sosunov E A, et al. Application of blebbistatin as an excitation–contraction uncoupler for electrophysiologic study of rat and rabbit hearts[J]. Heart rhythm, 2007, 4(5): 619-626.
[6]Wróbel A, Nowakowski Ł, Doboszewska U, et al. Blebbistatin reveals beneficial effects on the cystometric parameters in an animal model of detrusor overactivity[J]. Naunyn-schmiedeberg's Archives of Pharmacology, 2019, 392: 843-850.
[7]Wróbel A, Doboszewska U, Rechberger E, et al. Blebbistatin, a myosin II inhibitor, exerts antidepressant-like activity and suppresses detrusor overactivity in an animal model of depression coexisting with overactive bladder[J]. Neurotoxicity Research, 2019, 35: 196-207.
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *